Gentian Diagnostics AS (OSL:GENT) Total Stockholders Equity: kr182.7 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSL:GENT Gentian Diagnostics AS OSL:GENT
74 GF Score
Price kr39.60
GF Value kr59.98
Valuation Significantly Undervalued
View Full Analysis

What is Gentian Diagnostics AS Total Stockholders Equity?

Gentian Diagnostics AS OSL:GENT -0.25% 74 Total Stockholders Equity is kr182.7 Mil as of Jun. 2026. GuruFocus rates OSL:GENT with a GF Score™ of 74/100 and a GF Value™ of kr59.98 (Significantly Undervalued).

Gentian Diagnostics AS's Total Stockholders Equity for the quarter that ended in Jun. 2026 was kr182.7 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Gentian Diagnostics AS's Book Value per Share for the quarter that ended in Jun. 2026 was kr11.82. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Gentian Diagnostics AS's Debt-to-Equity for the quarter that ended in Jun. 2026 was 0.09.

Gentian Diagnostics AS  (OSL:GENT) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Gentian Diagnostics AS's Book Value per Share for the quarter that ended in Jun. 2026 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(182.697-0)/15.459
=11.82

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Gentian Diagnostics AS's Debt-to-Equity for the quarter that ended in Jun. 2026 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0 + 16.809) / 182.697
=0.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gentian Diagnostics AS Total Stockholders Equity Related Terms

Gentian Diagnostics AS Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Gentian Diagnostics AS's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gentian Diagnostics AS Total Stockholders Equity Chart

Gentian Diagnostics AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 174.77 154.17 146.64 194.05 204.96

Gentian Diagnostics AS Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 197.46 202.02 204.96 185.21 182.70
OSL:GENT
74GF Score
Gentian Diagnostics AS OSL:GENT
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of kr182.7 Mil mean?
Gentian Diagnostics AS (OSL:GENT) has a Total Stockholders Equity of kr182.7 Mil as of Jun. 2026. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Gentian Diagnostics AS and its competitors.
Is Gentian Diagnostics AS's Total Stockholders Equity too high?
Gentian Diagnostics AS's current Total Stockholders Equity is kr182.7 Mil. Overall, Gentian Diagnostics AS has a GF Score™ of 74/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Gentian Diagnostics AS's Total Stockholders Equity compare to ABT and SYK?
Gentian Diagnostics AS's Total Stockholders Equity of kr182.7 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Medical Devices & Instruments company?
A good Total Stockholders Equity depends on the Medical Devices & Instruments industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Gentian Diagnostics AS and its competitors. Gentian Diagnostics AS's current Total Stockholders Equity is kr182.7 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gentian Diagnostics AS stock overvalued right now?
Based on GuruFocus' analysis, Gentian Diagnostics AS (OSL:GENT) is currently considered Significantly Undervalued. The stock's GF Value™ is kr59.98, compared to a current price of kr39.60 — trading 34% below its estimated fair value. The current Total Stockholders Equity is kr182.7 Mil. Gentian Diagnostics AS's overall GF Score™ is 74/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Gentian Diagnostics AS (OSL:GENT), the current Total Stockholders Equity is kr182.7 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Gentian Diagnostics AS (OSL:GENT) Overvalued in 2026?

Based on GuruFocus' analysis, Gentian Diagnostics AS stock appears to be undervalued. The current stock price of kr39.60 is trading 34% below its estimated GF Value™ of kr59.98. GuruFocus considers Gentian Diagnostics AS to be Significantly Undervalued.

Key valuation signals for OSL:GENT:

  • Total Stockholders Equity: kr182.7 Mil
  • GF Value™: kr59.98 vs. price of kr39.60 (34% below fair value)
  • GF Score™: 74/100

No single metric tells the full story. See the OSL:GENT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Gentian Diagnostics AS Business Description

Other Exchanges GENTOo:Sweden6FK:Germany
Address Bjornasveien 5, Moss, NOR, 1596
Gentian Diagnostics AS operates as a medical diagnostics company in Norway. It develops and produces in vitro diagnostic reagents (IVD) for medical diagnostics and research. Its portfolio and pipeline of reagents span areas such as inflammation, severe infections, kidney diseases, heart failure, and veterinary healthcare. The company's product portfolio includes the Gentian Cystatin C Immunoassay, the GCAL circulating calprotectin immunoassay (IVDR), the Gentian Retinol Binding Protein (RBP), and the Gentian Canine CRP, among others. Geographically, it generates a majority of its revenue from Europe, followed by Asia and the United States of America.
74GF Score

Get the complete analysis for OSL:GENT

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr39.60
Price
kr59.98
GF Value